CN117503903A - A compound Chinese medicinal preparation containing cornu Cervi Pantotrichum polypeptide, and its preparation method - Google Patents
A compound Chinese medicinal preparation containing cornu Cervi Pantotrichum polypeptide, and its preparation method Download PDFInfo
- Publication number
- CN117503903A CN117503903A CN202311651869.8A CN202311651869A CN117503903A CN 117503903 A CN117503903 A CN 117503903A CN 202311651869 A CN202311651869 A CN 202311651869A CN 117503903 A CN117503903 A CN 117503903A
- Authority
- CN
- China
- Prior art keywords
- extract
- polypeptide
- pilose antler
- antler polypeptide
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 140
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 140
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 140
- 238000002360 preparation method Methods 0.000 title claims abstract description 138
- 150000001875 compounds Chemical class 0.000 title claims abstract description 57
- 210000003056 antler Anatomy 0.000 claims abstract description 99
- 239000000284 extract Substances 0.000 claims abstract description 77
- 238000002156 mixing Methods 0.000 claims abstract description 61
- 239000003814 drug Substances 0.000 claims abstract description 52
- 239000003094 microcapsule Substances 0.000 claims abstract description 47
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 21
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 21
- 241000208340 Araliaceae Species 0.000 claims abstract description 13
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 13
- 235000008434 ginseng Nutrition 0.000 claims abstract description 13
- 239000009636 Huang Qi Substances 0.000 claims abstract description 12
- 235000019206 astragalus extract Nutrition 0.000 claims abstract description 10
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 10
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940116229 borneol Drugs 0.000 claims abstract description 9
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 9
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 44
- 239000000843 powder Substances 0.000 claims description 43
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 21
- 235000010413 sodium alginate Nutrition 0.000 claims description 21
- 239000000661 sodium alginate Substances 0.000 claims description 21
- 229940005550 sodium alginate Drugs 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 16
- 239000003995 emulsifying agent Substances 0.000 claims description 15
- 239000000839 emulsion Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 229920001661 Chitosan Polymers 0.000 claims description 13
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 12
- 239000001110 calcium chloride Substances 0.000 claims description 12
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- 230000001804 emulsifying effect Effects 0.000 claims description 7
- 239000013049 sediment Substances 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 244000197580 Poria cocos Species 0.000 claims description 3
- 235000008599 Poria cocos Nutrition 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000005354 coacervation Methods 0.000 claims description 2
- 239000011162 core material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000001593 sorbitan monooleate Substances 0.000 claims description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 2
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 2
- 229950011392 sorbitan stearate Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000036039 immunity Effects 0.000 abstract description 11
- 230000002708 enhancing effect Effects 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 58
- 239000011812 mixed powder Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 239000002671 adjuvant Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 13
- 206010016256 fatigue Diseases 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 230000001766 physiological effect Effects 0.000 description 12
- 239000002245 particle Substances 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 239000000811 xylitol Substances 0.000 description 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 10
- 229960002675 xylitol Drugs 0.000 description 10
- 235000010447 xylitol Nutrition 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 238000003825 pressing Methods 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000010298 pulverizing process Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 241000282994 Cervidae Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000007605 air drying Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000002137 ultrasound extraction Methods 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920000867 polyelectrolyte Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical group [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
Abstract
The application relates to the field of traditional Chinese medicine compound preparations, and in particular discloses a traditional Chinese medicine compound preparation containing pilose antler polypeptide and a preparation method thereof. The traditional Chinese medicine compound preparation containing the pilose antler polypeptide comprises the following raw materials in parts by weight: 5-40 parts of pilose antler polypeptide microcapsule, 5-20 parts of ginseng extract, 5-20 parts of astragalus extract, 10-40 parts of poria extract and 3-10 parts of borneol extract; the preparation method comprises the following steps: mixing cornu Cervi Pantotrichum polypeptide microcapsule, ginseng radix extract, radix astragali extract, poria extract, and Borneolum Syntheticum extract, and making into compound Chinese medicinal preparation containing cornu Cervi Pantotrichum polypeptide. The traditional Chinese medicine compound preparation containing the pilose antler polypeptide has the advantages of resisting fatigue, enhancing immunity and improving sub-health state.
Description
Technical Field
The application relates to the field of traditional Chinese medicine compound preparations, in particular to a traditional Chinese medicine compound preparation containing pilose antler polypeptide and a preparation method thereof.
Background
Fatigue is a major manifestation of sub-health, and if the fatigue is in a fatigue state of overtime overload for a long time, the functions of important organs of the body can be disordered, a series of fatigue symptoms are generated, oxygen free radicals are accumulated, immune function is reduced, various diseases can be caused in the long time, and normal work and life of people are affected.
The health care product with the function of relieving physical fatigue is more and more paid attention to, wherein the traditional Chinese medicine has unique advantages in improving sub-health state because of being good at integrally conditioning human body, comprehensively adjusting the immunity of the human body, balancing the internal environment of yin and yang, qi and blood of the organism, promoting the balance of yin and yang and qi and blood of the human body and regulating qi and blood. The pilose antler is a traditional Chinese medicine material with health care effect, the pilose antler polypeptide is one of the most important physiologically active substances in the pilose antler, has multiple physiological functions, and has good physiological effect and strong physiological effect.
However, the stability of the deer antler polypeptide is poor, and the deer antler polypeptide is easy to be inactivated by hydrolysis, deformation, oxidation and the like, and the physiological utilization rate is poor, so the deer antler polypeptide needs to be improved.
Disclosure of Invention
In order to obtain a traditional Chinese medicine compound preparation containing the pilose antler polypeptide with high organism utilization rate, the application provides a traditional Chinese medicine compound preparation containing the pilose antler polypeptide and a preparation method thereof.
In a first aspect, the present application provides a compound traditional Chinese medicine preparation containing pilose antler polypeptide, which adopts the following technical scheme: a traditional Chinese medicine compound preparation containing pilose antler polypeptide comprises the following raw materials in parts by weight:
5-40 parts of pilose antler polypeptide microcapsule,
5-20 parts of ginseng extract,
5-20 parts of astragalus extract,
10-40 parts of poria cocos extract,
3-10 parts of borneol extract.
By adopting the technical scheme, the pilose antler polypeptide can increase the expression of skeletal muscle troponin mRNA, and increase muscle strength by up-regulating related genes of muscle contraction, so as to show anti-fatigue effect; the pilose antler polypeptide can improve the cellular immunity and humoral immunity capability and has obvious immunity promoting function; however, the stability of the hairy antler polypeptide is poor, and the hairy antler polypeptide is easy to hydrolyze, oxidize, denature and the like to cause complete loss of function, so the hairy antler polypeptide is coated by the microcapsule, so that the hairy antler polypeptide can be released at the effective position of the intestinal tract, the possibility of the hairy antler polypeptide inactivation is reduced, the action effect of the hairy antler polypeptide is improved, and the absorption and the utilization of the hairy antler polypeptide by the organism can be promoted;
the ginseng extract has the physiological effects of resisting tumor, enhancing organism immunity and delaying aging, has strong immunological activity, can promote organism immunity and enhance disease resistance, and the ginsenoside in the ginseng extract can play a role in enhancing physical ability and resisting fatigue from multiple ways of resisting free radicals, regulating sugar metabolism, reducing lactic acid accumulation after exercise, resisting central neurotransmitter disorder and the like;
the astragalus extract has the wide biological activities of strengthening spleen and tonifying middle-jiao, tonifying qi and strengthening exterior, resisting tumor, inflammation, sugar, oxidization and the like; the astragalus extract is helpful for promoting the expression of MHC molecules and immune co-stimulators on the surfaces of dendritic cells and promoting the secretion of cytokines so as to play the functions of antigen presentation and induction of T cell responses and effectively enhance the immunity of organisms;
the poria extract has the effects of strengthening spleen and stomach, calming heart and tranquilizing mind, and has the function of scavenging free radicals, and can relieve exercise fatigue caused by the free radicals, meanwhile, the poria extract can effectively inhibit thymus atrophy and spleen enlargement, and effectively enhance cellular immunity and humoral immunity; the borneol extract can promote the absorption and utilization of other medicinal components by the organism, and is beneficial to improving the physiological effect of the traditional Chinese medicine compound preparation;
according to the application, the pilose antler polypeptide microcapsule, the ginseng extract, the astragalus extract, the poria extract and the borneol extract are compatible, so that a stronger synergistic effect is achieved among various raw materials, the pilose antler polypeptide microcapsule has the effects of strengthening body, strengthening tendons and bones, relieving fatigue, enhancing immunity and preventing radiation to a certain extent, the utilization rate of the organism is high, the physiological effect is good, and the sub-health state of the organism can be effectively improved.
Preferably, the hairy antler polypeptide microcapsule is prepared by complex coacervation reaction by taking chitosan-alginate as a composite wall material and hairy antler polypeptide as a core material.
By adopting the technical scheme, the chitosan-alginate composite wall material can wrap the pilose antler polypeptide, so that the dissolution and the diffusion of the pilose antler polypeptide are limited to a certain extent, the purposes of slow release and protection are achieved, and the possibility of degradation of the pilose antler polypeptide in the stomach environment is reduced; and is beneficial to promoting the absorption of the pilose antler polypeptide by intestinal tracts and improving the bioavailability and the physiological effect of the pilose antler polypeptide.
Preferably, the preparation method of the pilose antler polypeptide microcapsule comprises the following steps:
mixing the pilose antler polypeptide solution with the sodium alginate solution to obtain a blend solution I, mixing the blend solution with white oil containing an emulsifier, and stirring and emulsifying to obtain an emulsion;
mixing chitosan solution with calcium chloride to obtain blend solution II, regulating pH value of the second blend solution to 4-7, dripping the emulsion into the blend solution II, stirring, standing for settling, separating out sediment, washing, and freeze drying to obtain cornu Cervi Pantotrichum polypeptide microcapsule.
By adopting the technical scheme, calcium ions form gel-state complex with sodium alginate through coordination bonds in sodium alginate molecules, carboxyl groups with negative charges on the sodium alginate and primary amino groups with positive charges on chitosan are mutually attracted to form polyelectrolyte membranes, and the polyelectrolyte membranes are condensed from the solution to wrap antler polypeptides to form the antler polypeptide microcapsules.
Preferably, in the blend liquid I, the mass fraction of the sodium alginate is 2-5%, and the concentration of the pilose antler polypeptide is 5-15mg/ml; in the blend liquid II, the mass fraction of chitosan is 1-4%; the mass fraction of the calcium chloride is 1-4%; in the white oil containing the emulsifier, the mass concentration of the emulsifier is 0.5-2%; the volume ratio of the white oil containing the emulsifying agent to the blending liquid I is (0.5-2) 1; the volume ratio of the blend liquid I to the blend liquid II is (1-2): 1.
Preferably, the emulsifier is one or a combination of more of sorbitan stearate and sorbitan monooleate polyoxyethylene ether.
By adopting the technical scheme, the emulsification is beneficial to fully dispersing the pilose antler polypeptide in the solution, so that the particle size of the pilose antler polypeptide microcapsule is more uniform.
Preferably, the particle size of the hairy antler polypeptide microcapsule is 50-200 μm.
Preferably, the traditional Chinese medicine compound preparation comprises the following raw materials in parts by weight: 25-30 parts of pilose antler polypeptide microcapsule, 8-12 parts of ginseng extract, 15-18 parts of astragalus extract, 28-32 parts of poria extract and 5-8 parts of borneol extract.
By adopting the technical scheme, the compatibility of various traditional Chinese medicine components is optimized, so that the traditional Chinese medicine compound preparation has better physiological effect.
Preferably, the Chinese herbal compound preparation is selected from one of tablets, soft capsules, pills and oral liquid.
In a second aspect, the present application provides a method for preparing a traditional Chinese medicine compound preparation containing pilose antler polypeptide, which adopts the following technical scheme:
a preparation method of a traditional Chinese medicine compound preparation containing cornu Cervi Pantotrichum polypeptide comprises the following steps:
mixing cornu Cervi Pantotrichum polypeptide microcapsule, ginseng radix extract, radix astragali extract, poria extract, and Borneolum Syntheticum extract, and making into compound Chinese medicinal preparation containing cornu Cervi Pantotrichum polypeptide.
Preferably, the preparation method of the pilose antler polypeptide microcapsule comprises the following steps:
extracting cornu Cervi Pantotrichum powder with supercritical carbon dioxide, separating, and purifying to obtain cornu Cervi Pantotrichum polypeptide extract;
dissolving cornu Cervi Pantotrichum polypeptide extract in acetic acid solution to obtain cornu Cervi Pantotrichum polypeptide solution; mixing the pilose antler polypeptide solution with the sodium alginate solution to obtain a blend solution I, mixing the blend solution with white oil containing an emulsifier, and stirring and emulsifying to obtain an emulsion;
mixing chitosan solution with calcium chloride to obtain blend solution II, regulating pH value of the second blend solution to 4-7, dripping the emulsion into the blend solution II, stirring, standing for settling, separating out sediment, washing, and freeze drying to obtain cornu Cervi Pantotrichum polypeptide microcapsule.
By adopting the technical scheme, the traditional Chinese medicine compound preparation with high utilization rate and good physiological effect of organisms can be obtained, and the traditional Chinese medicine compound preparation has multiple physiological effects of relieving fatigue, enhancing immunity, building up body and the like, and effectively improves sub-health state of organisms.
In summary, the present application has the following beneficial effects:
1. the pilose antler polypeptide microcapsule, the ginseng extract, the astragalus extract, the poria extract and the borneol extract are compatible, so that the raw materials have strong synergistic effect, have the effects of building up body, strengthening tendons and bones, relieving fatigue and enhancing immunity, have high utilization rate of organisms and good physiological effect, and can effectively improve sub-health states of the organisms;
2. in the application, the hairy antler polypeptide is coated by the microcapsule, so that the hairy antler polypeptide can be released at the effective position of the intestinal tract, the possibility of the hairy antler polypeptide inactivation is reduced, the action effect of the hairy antler polypeptide is improved, and the absorption and the utilization of the hairy antler polypeptide by the organism can be promoted.
Detailed Description
The present application is described in further detail below with reference to examples.
Preparation example
Preparation example 1
The preparation example provides a pilose antler polypeptide microcapsule, which is prepared by the following steps:
cutting cornu Cervi Pantotrichum, cleaning with distilled water pre-cooled at 4deg.C, pulverizing to 200 mesh to obtain cornu Cervi Pantotrichum powder, extracting with supercritical carbon dioxide under 30Mpa and carbon dioxide flow rate of 20L/h at 40deg.C for 120min, vacuum separating in extraction kettle, mixing the separated product with 95% ethanol at 4deg.C, standing at 4deg.C for settling, centrifuging to obtain supernatant, rotary evaporating, concentrating, and lyophilizing to obtain cornu Cervi Pantotrichum polypeptide extract; dissolving cornu Cervi Pantotrichum polypeptide extract in 0.05mol/L acetic acid solution to obtain cornu Cervi Pantotrichum polypeptide solution with concentration of 25 mg/ml; dissolving sodium alginate in water to obtain sodium alginate solution; mixing the hairy antler polypeptide solution with the sodium alginate solution to ensure that the final concentration of the hairy antler polypeptide is 10mg/ml and the mass fraction of the sodium alginate is 2%, thus obtaining a blend solution I; mixing the blend solution with white oil containing 1wt% of emulsifier according to the volume ratio of 1:0.5, stirring for 20min at 800r/min, and emulsifying to obtain emulsion;
dissolving chitosan in 0.05mol/L acetic acid solution, dissolving calcium chloride in the acetic acid solution to enable the mass fraction of the chitosan to be 2% and the mass fraction of the calcium chloride to be 2%, obtaining a blend solution II, and adjusting the pH value of the second blend solution to be 5.5; dripping the emulsion into the blend II according to the volume ratio of 1:1, stirring for 30min at 600r/min, standing still and settling for 4h, separating out sediment, washing with petroleum ether and isopropanol for three times respectively, and freeze-drying to obtain the pilose antler polypeptide microcapsule, wherein the particle size range is 50-200 μm, and the microcapsule with the particle size range of 100-150 μm reaches 74% by observing under a laser particle size analyzer and a microscope.
Preparation example 2
The preparation example differs from the preparation example 1 only in that the preparation method of the pilose antler polypeptide microcapsule is as follows:
dissolving cornu Cervi Pantotrichum polypeptide extract in 0.05mol/L acetic acid solution to obtain cornu Cervi Pantotrichum polypeptide solution with concentration of 25 mg/ml; dissolving sodium alginate in water to obtain sodium alginate solution; mixing the hairy antler polypeptide solution with the sodium alginate solution to ensure that the final concentration of the hairy antler polypeptide is 10mg/ml and the mass fraction of the sodium alginate is 2%, thus obtaining a blend solution I; mixing the blending solution with white oil containing 1wt% of emulsifier according to the volume ratio of 1:1, stirring for 20min at 800r/min, and emulsifying to obtain emulsion;
dissolving chitosan in 0.05mol/L acetic acid solution, dissolving calcium chloride in the acetic acid solution to enable the mass fraction of the chitosan to be 2% and the mass fraction of the calcium chloride to be 2%, obtaining a blend solution II, and adjusting the pH value of the second blend solution to be 5.5; dripping the emulsion into the blend II according to the volume ratio of 2:1, stirring for 30min at 600r/min, standing still and settling for 4h, separating out sediment, washing with petroleum ether and isopropanol for three times respectively, and freeze-drying to obtain the pilose antler polypeptide microcapsule, wherein the particle size range is 50-200 μm, and the microcapsule with the particle size range of 100-150 μm reaches 72% by observing under a laser particle size analyzer and a microscope.
Preparation example 3
The preparation example differs from the preparation example 1 only in that the preparation method of the pilose antler polypeptide microcapsule is as follows:
dissolving cornu Cervi Pantotrichum polypeptide extract in 0.05mol/L acetic acid solution to obtain cornu Cervi Pantotrichum polypeptide solution with concentration of 25 mg/ml; dissolving sodium alginate in water to obtain sodium alginate solution; mixing the hairy antler polypeptide solution with the sodium alginate solution to ensure that the final concentration of the hairy antler polypeptide is 15mg/ml and the mass fraction of the sodium alginate is 5%, thus obtaining a blend solution I; mixing the blend solution with white oil containing 1wt% of emulsifier according to the volume ratio of 1:0.5, stirring for 20min at 800r/min, and emulsifying to obtain emulsion;
dissolving chitosan in 0.05mol/L acetic acid solution, dissolving calcium chloride in the acetic acid solution to enable the mass fraction of the chitosan to be 4% and the mass fraction of the calcium chloride to be 4%, obtaining a blend solution II, and adjusting the pH value of the second blend solution to be 5.5; dripping the emulsion into the blend II according to the volume ratio of 1:1, stirring for 30min at 600r/min, standing still and settling for 4h, separating out sediment, washing with petroleum ether and isopropanol for three times respectively, and freeze-drying to obtain the pilose antler polypeptide microcapsule, wherein the particle size range is 50-200 μm, and the microcapsule with the particle size range of 100-150 μm reaches 68% by observing under a laser particle size analyzer and a microscope.
Preparation example 4
The preparation example provides a ginseng extract, and the preparation method comprises the following steps:
cleaning Ginseng radix, air drying, pulverizing, adding 45% ethanol water solution at a feed liquid ratio of 1:5g/mL into an ultrasonic extraction kettle, ultrasonic extracting for 2 hr, filtering with gauze, concentrating under reduced pressure at low temperature, and freeze drying to obtain Ginseng radix extract powder.
Preparation example 5
The preparation example provides an astragalus extract, and the preparation method comprises the following steps:
cleaning radix astragali, air drying, pulverizing, adding into ultrasonic extraction kettle, adding water at a feed-liquid ratio of 1:8g/mL, ultrasonic extracting at 50deg.C for 2 hr, filtering with gauze, concentrating under reduced pressure at low temperature, and freeze drying to obtain radix astragali extract powder.
Preparation example 6
The preparation example provides a poria cocos extract, which is prepared by the following steps:
cleaning Poria, air drying, pulverizing, adding into ultrasonic extraction kettle, adding 45% ethanol water solution at a feed-liquid ratio of 1:8g/mL, ultrasonic extracting for 2 hr, filtering with gauze, concentrating under reduced pressure at low temperature, and freeze drying to obtain Poria extract powder.
Preparation example 7
The preparation example provides a borneol extract, and the preparation method comprises the following steps:
cleaning Poria, air drying, pulverizing, adding into ultrasonic extraction kettle, adding 45% ethanol water solution at a feed liquid ratio of 1:5g/mL, ultrasonic extracting for 2 hr, filtering with gauze, concentrating under reduced pressure at low temperature, and freeze drying to obtain Borneolum Syntheticum extract powder.
Examples
Example 1
The embodiment discloses a traditional Chinese medicine compound preparation containing pilose antler polypeptide, which is prepared by the following steps:
mixing cornu Cervi Pantotrichum polypeptide microcapsule 200g prepared in preparation example 1, ginseng radix extract powder 150g prepared in preparation example 4, radix astragali extract powder 80g prepared in preparation example 5, poria extract powder 350g prepared in preparation example 6, and Borneolum Syntheticum extract powder 30g prepared in preparation example 7 to obtain mixed powder; mixing xylitol and starch paste according to a mass ratio of 1:2 to prepare auxiliary materials; mixing the mixed powder with adjuvants, adding magnesium stearate accounting for 1% of the total mass of the mixed powder and adjuvants, mixing, and pressing into tablet with specification of 0.8 g/tablet to obtain traditional Chinese medicine compound preparation containing cornu Cervi Pantotrichum polypeptide.
Example 2
The difference between this example and example 1 is that the preparation method of the traditional Chinese medicine compound preparation containing the pilose antler polypeptide is as follows: mixing cornu Cervi Pantotrichum polypeptide microcapsule 350g prepared in preparation example 1, ginseng radix extract powder 50g prepared in preparation example 4, radix astragali extract powder 190g prepared in preparation example 5, poria extract powder 140g prepared in preparation example 6, and Borneolum Syntheticum extract powder 90g prepared in preparation example 7 to obtain mixed powder; mixing xylitol and starch paste according to a mass ratio of 1:2 to prepare auxiliary materials; mixing the mixed powder with adjuvants, adding magnesium stearate accounting for 1% of the total mass of the mixed powder and adjuvants, mixing, and pressing into tablet with specification of 0.8 g/tablet to obtain traditional Chinese medicine compound preparation containing cornu Cervi Pantotrichum polypeptide.
Example 3
The difference between this example and example 1 is that the preparation method of the traditional Chinese medicine compound preparation containing the pilose antler polypeptide is as follows: mixing cornu Cervi Pantotrichum polypeptide microcapsule 400g prepared in preparation example 1, ginseng radix extract powder 50g prepared in preparation example 4, radix astragali extract powder 200g prepared in preparation example 5, poria extract powder 100g prepared in preparation example 6, and Borneolum Syntheticum extract powder 60g prepared in preparation example 7 to obtain mixed powder; mixing xylitol and starch paste according to a mass ratio of 1:2 to prepare auxiliary materials; mixing the mixed powder with adjuvants, adding magnesium stearate accounting for 1% of the total mass of the mixed powder and adjuvants, mixing, and pressing into tablet with specification of 0.8 g/tablet to obtain traditional Chinese medicine compound preparation containing cornu Cervi Pantotrichum polypeptide.
Example 4
The difference between this example and example 1 is that the preparation method of the traditional Chinese medicine compound preparation containing the pilose antler polypeptide is as follows: mixing cornu Cervi Pantotrichum polypeptide microcapsule 50g prepared in preparation example 1, ginseng radix extract powder 200g prepared in preparation example 4, radix astragali extract powder 50g prepared in preparation example 5, poria extract powder 400g prepared in preparation example 6, and Borneolum Syntheticum extract powder 100g prepared in preparation example 7 to obtain mixed powder; mixing xylitol and starch paste according to a mass ratio of 1:2 to prepare auxiliary materials; mixing the mixed powder with adjuvants, adding magnesium stearate accounting for 1% of the total mass of the mixed powder and adjuvants, mixing, and pressing into tablet with specification of 0.8 g/tablet to obtain traditional Chinese medicine compound preparation containing cornu Cervi Pantotrichum polypeptide.
Example 5
The difference between this example and example 1 is that the preparation method of the traditional Chinese medicine compound preparation containing the pilose antler polypeptide is as follows:
mixing cornu Cervi Pantotrichum polypeptide microcapsule 250g prepared in preparation example 1, ginseng radix extract powder 120g prepared in preparation example 4, radix astragali extract powder 150g prepared in preparation example 5, poria extract powder 300g prepared in preparation example 6, and Borneolum Syntheticum extract powder 70g prepared in preparation example 7 to obtain mixed powder; mixing xylitol and starch paste according to a mass ratio of 1:2 to prepare auxiliary materials; mixing the mixed powder with adjuvants, adding magnesium stearate accounting for 1% of the total mass of the mixed powder and adjuvants, mixing, and pressing into tablet with specification of 0.8 g/tablet to obtain traditional Chinese medicine compound preparation containing cornu Cervi Pantotrichum polypeptide.
Example 6
The difference between this example and example 1 is that the preparation method of the traditional Chinese medicine compound preparation containing the pilose antler polypeptide is as follows:
mixing cornu Cervi Pantotrichum polypeptide microcapsule 280g prepared in preparation example 1, ginseng radix extract powder 100g prepared in preparation example 4, radix astragali extract powder 160g prepared in preparation example 5, poria extract powder 320g prepared in preparation example 6, and Borneolum Syntheticum extract powder 50g prepared in preparation example 7 to obtain mixed powder; mixing xylitol and starch paste according to a mass ratio of 1:2 to prepare auxiliary materials; mixing the mixed powder with adjuvants, adding magnesium stearate accounting for 1% of the total mass of the mixed powder and adjuvants, mixing, and pressing into tablet with specification of 0.8 g/tablet to obtain traditional Chinese medicine compound preparation containing cornu Cervi Pantotrichum polypeptide.
Example 7
The difference between this example and example 1 is that the preparation method of the traditional Chinese medicine compound preparation containing the pilose antler polypeptide is as follows:
mixing cornu Cervi Pantotrichum polypeptide microcapsule 300g prepared in preparation example 1, ginseng radix extract powder 80g prepared in preparation example 4, radix astragali extract powder 180g prepared in preparation example 5, poria extract powder 280g prepared in preparation example 6, and Borneolum Syntheticum extract powder 80g prepared in preparation example 7 to obtain mixed powder; mixing xylitol and starch paste according to a mass ratio of 1:2 to prepare auxiliary materials; mixing the mixed powder with adjuvants, adding magnesium stearate accounting for 1% of the total mass of the mixed powder and adjuvants, mixing, and pressing into tablet with specification of 0.8 g/tablet to obtain traditional Chinese medicine compound preparation containing cornu Cervi Pantotrichum polypeptide.
Example 8
This example differs from example 1 only in that the deer antler polypeptide microcapsule was prepared by preparation example 2.
Example 9
This example differs from example 1 only in that the deer antler polypeptide microcapsule was prepared by preparation example 3.
Comparative example
The comparative example differs from example 1 only in that the preparation method of the traditional Chinese medicine compound preparation containing the pilose antler polypeptide is as follows:
cutting cornu Cervi Pantotrichum, cleaning with distilled water precooled at 4deg.C, pulverizing to obtain cornu Cervi Pantotrichum powder, mixing 1kg cornu Cervi Pantotrichum powder with 5kg 0.1mol/L acetic acid solution precooled at 4deg.C, pulping to obtain homogenate, treating with 100W microwave for 15min, centrifuging, collecting supernatant, mixing with 95% ethanol at 4deg.C to reach protein concentration of 50%, settling in 4deg.C, centrifuging, collecting supernatant, rotary evaporating, concentrating, and lyophilizing to obtain cornu Cervi Pantotrichum polypeptide extract;
mixing 200g of the polypeptide extract of cornu Cervi Pantotrichum, 150g of the Ginseng radix extract powder prepared in preparation example 4, 80g of the astragali radix extract powder prepared in preparation example 5, 350g of the Poria extract powder prepared in preparation example 6, and 30g of the Borneolum Syntheticum extract powder prepared in preparation example 7 to obtain mixed powder; mixing xylitol and starch paste according to a mass ratio of 1:2 to prepare auxiliary materials; mixing the mixed powder with adjuvants, adding magnesium stearate 1% of the total mass of the mixed powder and adjuvants, mixing, and pressing into tablet with specification of 0.8 g/tablet to obtain traditional Chinese medicine compound preparation containing cornu Cervi Pantotrichum polypeptide.
Performance test
The test is carried out by adopting a Kunming mouse with the age of 4 weeks, the weight of the mouse is 20+/-2 g, the mouse is fed with standard pellet feed for free ingestion and drinking water under the environment of 12 hours of alternate daytime/night circulation, the temperature is 20+/-1 ℃, the humidity is 55+/-10%, and the ventilation times are 20+/-2 times/hour; mice were divided into 11 groups of 6 mice each at random according to different experiments. The 1 st to 10 th groups are test groups, the traditional Chinese medicine compound preparations prepared in the examples 1 to 9 and the comparative example are sequentially taken as the tested medicines for administration, the traditional Chinese medicine compound preparations are rolled into powder and fed along with the feed, and the administration dosage is 1.0g/kg. The 11 th group is a control group, xylitol and starch paste are mixed according to the mass ratio of 1:2, then magnesium stearate accounting for 1 percent of the total mass of the xylitol and the starch paste is added, the mixture is uniformly mixed and pressed into tablets of 0.8 g/tablet, and the tablets are rolled into powder to be fed together with feed, and the dosage of the administration is 1.0g/kg. The following tests were performed after 30 days of dosing:
test one: and (3) load swimming test: after the test drug is given for 30min at the last time, placing the mice in a swimming box at 25 ℃, loading lead skin with 5% weight at the root of the mice at the depth of 35cm, recording the time from the beginning of the swimming of the mice to the death as the swimming time of the mice, and taking the average value of each group to obtain the swimming time of the exhaustion;
and II, testing: and (3) measuring the content of lactic acid: after the test drug is given for 30min at the last time, 20 mu L of capillary glass tube inner canthus vein is used for blood collection, the mixture is added into a 5mL test tube containing 0.48mL 1 percent NaF solution, 1.5mL protein precipitant is added for uniform mixing, centrifugation is carried out for 15min at 3000r/min, supernatant fluid is left, and the lactic acid content is measured by using a whole blood lactic acid test kit (product number: A019-1-1); no load is applied after blood collection, the swimming is stopped after swimming in a swimming box at 25 ℃ for 10min, 20 mu L of blood is immediately collected, 20 mu L of blood is collected again after 20min of rest, and the lactic acid content is measured by the same method.
And (3) testing: serum hemolysin level (HC) 50 ) And (3) measuring:
on day 25 of dosing, mice were subjected to sensitization experiments: each mouse was intraperitoneally injected with 2% packed Sheep Red Blood Cells (SRBC) at a dose of 0.2mL per mouse. After the 30 th day of administration, the mice are fasted for 12 hours, anesthetized by diethyl ether, subjected to eyeball extraction and blood collection, and subjected to centrifugation after standing for 24 hours at 4 ℃ to separate serum; 10. Mu.L of serum was taken and diluted with 1mL of diluted SA buffer.
Dividing a 96-well culture plate into blank wells, test wells and control wells, and adding 100 mu L/well of diluted SA buffer into the blank wells; 100. Mu.L of serum from the test or control group diluted with SA buffer was added to each of the test and control wells, respectively. After the sample is filled, 50 mu L of packed sheep red blood cells (10% (v/v)) and 100 mu L of complement are sequentially added into the blank hole and the sample hole. After the film coating, the 96-well culture plate is placed in a constant-temperature water bath at 37 ℃ for 30min, taken out, placed in a centrifuge and centrifuged for 10min at a rotational speed of 1500r/min. 50. Mu.L of the supernatant from each well was precisely aspirated and placed in another new 96-well plate, after which 150. Mu.L of Wen Ji reagent was added to each well. Meanwhile, half hemolysis wells are arranged in a new 96-well culture plate, 10% (v/v) packed Sheep Red Blood Cells (SRBC) are added into the half hemolysis wells, 12.5 mu L of the SRBC is added, and then a litwell reagent is added to be added to the 200 mu L. Vibrating, mixing, coating, standing for 10min, measuring optical density value at 540nm with full-automatic enzyme-labeled instrument, and calculating HC 50 Values. The content of hemolysin in serum was determined by half-value hemolysis (HC 50 ) The expression is as follows:
HC 50 = ((experimental group optical density value-blank group optical density value)/(optical density value at SRBC half hemolysis-blank group optical density value)) × dilution.
The results are summarized in Table 1.
TABLE 1
It can be seen from the combination of test groups 1-4 and control group and the combination of table 1 that the compound Chinese medicinal preparation prepared by the formula and the method disclosed by the application can enhance the exercise capacity of mice, has an inhibiting effect on the increase of blood lactic acid of the mice after exercise, can accelerate fatigue elimination and physical recovery, has obvious anti-fatigue effect, can increase the serum hemolysin content of the mice, is beneficial to improving the cellular immunity and humoral immunity level of the mice, and enhances the immunity of the mice.
It can be seen from the combination of test group 1, test groups 8-9 and test group 10 and the combination of table 1 that the addition of the pilose antler polypeptide into the compound preparation in the form of microcapsules is helpful for promoting the further improvement of the effect of the compound preparation. This is probably because the microcapsule reduces the possibility of inactivation of the pilose antler polypeptide in the stomach environment, so that the pilose antler polypeptide can be released in the intestinal tract environment, and the absorption of the pilose antler polypeptide by the intestinal tract is facilitated, and the physiological effect of the pilose antler polypeptide is promoted to be fully exerted.
It can be seen from the combination of test groups 1-7 and the combination of table 1 that the use amount of each raw material is further optimized, so that the improvement of the drug effect of the traditional Chinese medicine compound preparation can be further promoted, and the traditional Chinese medicine compound preparation has better physiological effects of resisting fatigue and enhancing immunity.
The present embodiment is merely illustrative of the present application and is not intended to be limiting, and those skilled in the art, after having read the present specification, may make modifications to the present embodiment without creative contribution as required, but is protected by patent laws within the scope of the claims of the present application.
Claims (10)
1. A traditional Chinese medicine compound preparation containing pilose antler polypeptide is characterized by comprising the following raw materials in parts by weight:
5-40 parts of pilose antler polypeptide microcapsule,
5-20 parts of ginseng extract,
5-20 parts of astragalus extract,
10-40 parts of poria cocos extract,
3-10 parts of borneol extract.
2. The compound traditional Chinese medicine preparation containing the pilose antler polypeptide according to claim 1, which is characterized in that: the pilose antler polypeptide microcapsule is prepared by complex coacervation reaction by taking chitosan-alginate as a composite wall material and pilose antler polypeptide as a core material.
3. The compound traditional Chinese medicine preparation containing the pilose antler polypeptide according to claim 2, which is characterized in that: the preparation method of the pilose antler polypeptide microcapsule comprises the following steps:
mixing the pilose antler polypeptide solution with the sodium alginate solution to obtain a blend solution I, mixing the blend solution with white oil containing an emulsifier, and stirring and emulsifying to obtain an emulsion;
mixing chitosan solution with calcium chloride to obtain blend solution II, regulating pH value of the second blend solution to 4-7, dripping the emulsion into the blend solution II, stirring, standing for settling, separating out sediment, washing, and freeze drying to obtain cornu Cervi Pantotrichum polypeptide microcapsule.
4. The compound traditional Chinese medicine preparation containing the pilose antler polypeptide according to claim 3, which is characterized in that: in the blend liquid I, the mass fraction of sodium alginate is 2-5%, and the concentration of the pilose antler polypeptide is 5-15mg/ml; in the blend liquid II, the mass fraction of chitosan is 1-4%; the mass fraction of the calcium chloride is 1-4%;
in the white oil containing the emulsifier, the mass concentration of the emulsifier is 0.5-2%; the volume ratio of the white oil containing the emulsifying agent to the blending liquid I is (0.5-2) 1;
the volume ratio of the blend liquid I to the blend liquid II is (1-2): 1.
5. The compound traditional Chinese medicine preparation containing the pilose antler polypeptide according to claim 4, which is characterized in that: the emulsifier is one or a combination of more of sorbitan stearate and sorbitan monooleate polyoxyethylene ether.
6. The compound traditional Chinese medicine preparation containing the pilose antler polypeptide according to claim 2, which is characterized in that: the grain size of the pilose antler polypeptide microcapsule is 50-200 mu m.
7. The compound traditional Chinese medicine preparation containing the pilose antler polypeptide according to claim 2, which is characterized in that: comprises the following raw materials in parts by weight: 25-30 parts of pilose antler polypeptide microcapsule, 8-12 parts of ginseng extract, 15-18 parts of astragalus extract, 28-32 parts of poria extract and 5-8 parts of borneol extract.
8. The compound traditional Chinese medicine preparation containing the pilose antler polypeptide according to claim 1, which is characterized in that: the Chinese medicinal compound preparation is selected from one of tablets, soft capsules, pills and oral liquid.
9. A method for preparing a traditional Chinese medicine compound preparation containing pilose antler polypeptide as claimed in any one of claims 1-8, which is characterized in that: the method comprises the following steps:
mixing cornu Cervi Pantotrichum polypeptide microcapsule, ginseng radix extract, radix astragali extract, poria extract, and Borneolum Syntheticum extract, and making into compound Chinese medicinal preparation containing cornu Cervi Pantotrichum polypeptide.
10. The method for preparing the compound Chinese medicinal preparation containing the pilose antler polypeptide according to claim 9, which is characterized in that: the preparation method of the pilose antler polypeptide microcapsule comprises the following steps:
extracting cornu Cervi Pantotrichum powder with supercritical carbon dioxide, separating, and purifying to obtain cornu Cervi Pantotrichum polypeptide extract;
dissolving cornu Cervi Pantotrichum polypeptide extract in acetic acid solution to obtain cornu Cervi Pantotrichum polypeptide solution; mixing the pilose antler polypeptide solution with the sodium alginate solution to obtain a blend solution I, mixing the blend solution with white oil containing an emulsifier, and stirring and emulsifying to obtain an emulsion;
mixing chitosan solution with calcium chloride to obtain blend solution II, regulating pH value of the second blend solution to 4-7, dripping the emulsion into the blend solution II, stirring, standing for settling, separating out sediment, washing, and freeze drying to obtain cornu Cervi Pantotrichum polypeptide microcapsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311651869.8A CN117503903A (en) | 2023-12-05 | 2023-12-05 | A compound Chinese medicinal preparation containing cornu Cervi Pantotrichum polypeptide, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311651869.8A CN117503903A (en) | 2023-12-05 | 2023-12-05 | A compound Chinese medicinal preparation containing cornu Cervi Pantotrichum polypeptide, and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117503903A true CN117503903A (en) | 2024-02-06 |
Family
ID=89754951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311651869.8A Pending CN117503903A (en) | 2023-12-05 | 2023-12-05 | A compound Chinese medicinal preparation containing cornu Cervi Pantotrichum polypeptide, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117503903A (en) |
-
2023
- 2023-12-05 CN CN202311651869.8A patent/CN117503903A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102178734B (en) | Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases and resisting fatigue | |
| CN1923256A (en) | Medicinal composition, its preparing method and quality controlling means | |
| CN114246918A (en) | Traditional Chinese medicine composition for treating hashimoto thyroiditis and preparation method thereof | |
| CN117503903A (en) | A compound Chinese medicinal preparation containing cornu Cervi Pantotrichum polypeptide, and its preparation method | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN105250989A (en) | Donkey-hide glue small peptide composition for resisting fatigue | |
| CN109288904A (en) | The Chinese medicine composition and its preparation method and application of prevention or treatment arrhythmia cordis | |
| JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
| WO2021249286A1 (en) | New drug formula for immunotherapy and tablet structure thereof | |
| CN108498568A (en) | Chinese patent drug, medical food and the preparation method of autoimmune and immune related diseases are treated with Goat Placenta or embryo | |
| CN104998085B (en) | A kind of Traditional Chinese medicine compound composition of improving immunocompetence and preparation method thereof | |
| CN111588763B (en) | Thrombus dredging medicine, preparation method and content determination method | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN103735621A (en) | Chinese medicinal composition with blood lipid reducing and immunity enhancing effects | |
| CN110448625B (en) | Traditional Chinese medicine composition for treating hypoxic kidney injury diseases, preparation method and application thereof | |
| CN113952419A (en) | Pharmaceutical composition for chronic renal failure and preparation method and application thereof | |
| CN1557416A (en) | Medicine preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN105288501A (en) | Traditional Chinese medicine composition containing folium artemisiae argyi and treating obesity | |
| CN110064016A (en) | A kind of Chinese medicine composition and preparation method thereof adjusting chronic kidney disease immune state | |
| CN100528199C (en) | Traditional Chinese medicine compound for expelling tritium | |
| CN1895504A (en) | Chinese medicine for treating osteoporosis and its preparation | |
| CN1188000A (en) | Intestinal microecological preparation | |
| CN109528827B (en) | Pharmaceutical composition and preparation for promoting blood circulation, removing blood stasis and reducing blood fat and preparation method thereof | |
| CN109224059A (en) | compound preparation and preparation method thereof | |
| CN1251723C (en) | Pharmaceutical composition for treating idiopathic thrombocytopenic purpura of blood heat type and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |